Amgen’s Dazodalibep Marks Potential Turning Point in the Quest for Sjögren’s Disease Treatment on September 23, 2026 Posted by
The Eternal Blade: Dexter Jackson’s Legacy and His Impending Enshrinement in the International Sports Hall of Fame on September 23, 2026 Posted by
Legal Battle Intensifies Over Medicaid Work Requirements and Medical Frailty Definitions on September 23, 2026 Posted by
The Architect of Austerity: Brian Blase and the Great Medicaid Reconfiguration on September 23, 2026 Posted by
The Digital Frontier: Evaluating the Global Crackdown on Youth Social Media Use on September 23, 2026 Posted by
Breaking the Cycle of Resistance: Baylor Researchers Unveil Promising New Cancer Therapeutic, CS18 on September 23, 2026 Posted by
Amgen’s Dazodalibep Marks Potential Turning Point in the Quest for Sjögren’s Disease Treatment on September 23, 2026 Posted by
The Eternal Blade: Dexter Jackson’s Legacy and His Impending Enshrinement in the International Sports Hall of Fame on September 23, 2026 Posted by
Legal Battle Intensifies Over Medicaid Work Requirements and Medical Frailty Definitions on September 23, 2026 Posted by
Posted in Cardiovascular Recovery Preventive Cardiology Breakthrough: PCSK9 Inhibitor Evolocumab Shows Promise for High-Risk Diabetes Patients on August 7, 2026
Posted in Medical Innovations A New Frontier in Cardiology: FDA Approves Lipfendra, the First Oral PCSK9 Inhibitor on July 17, 2026
Posted in Medical Innovations A New Era in Cardiology: FDA Greenlights Enlicitide, the First Oral PCSK9 Inhibitor on July 16, 2026
Posted in Digital Health Tools Roche Claims Breakthrough in Lung Cancer Treatment with Next-Generation KRAS Inhibitor on July 3, 2026
Posted in Digital Health Tools A New Frontier in Myelofibrosis: Eli Lilly’s Novel JAK2 Inhibitor Shows Promise in Early Trials on June 21, 2026
Posted in Medical Innovations Setback in the Quest for a Parkinson’s Breakthrough: Biogen and Denali’s LRRK2 Inhibitor Fails Mid-Stage Trial on May 24, 2026 rifanmuazin
Posted in Digital Health Tools A Stalled Frontier: The Clinical Failure of Biogen and Denali’s LRRK2 Inhibitor in Parkinson’s Disease on May 22, 2026 rifanmuazin
Posted in Cardiovascular Recovery A New Frontier in Hypertension: FDA Approves Baxdrostat as First-in-Class Aldosterone Synthase Inhibitor on May 19, 2026 rifanmuazin
Posted in Digital Health Tools A New Frontier in Oncology: FDA Approves Beqalzi as First-in-Class BCL-2 Inhibitor for Mantle Cell Lymphoma on May 15, 2026 rifanmuazin
